MDV3100 for the treatment of prostate cancer.
Mukherji D, Pezaro CJ, De-Bono JS.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.651125 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för cabazitaxel. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
15 hitsNovel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O, Michels RM, Massard C, de Bono JS.
Oncologist · research-article; review; journal article · DOI 10.1634/theoncologist.2010-0412Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.
de Bruijn P, de Graan AJ, Nieuweboer A, Mathijssen RH, Lam MH, de Wit R, Wiemer EA, Loos WJ.
J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2011.10.010Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M, Ong M, Winquist E.
Curr Opin Support Palliat Care · research support, non-u.s. gov't; review; journal article · DOI 10.1097/spc.0b013e32834903aaEmerging treatment options for patients with castration-resistant prostate cancer.
George D, Moul JW.
Prostate · research support, non-u.s. gov't; review; journal article · DOI 10.1002/pros.21435Cabazitaxel: a novel microtubule inhibitor.
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X.
Drugs · review; journal article · DOI 10.2165/11591390-000000000-00000Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells.
Han B, Fujimoto N, Kobayashi M, Matsumoto T.
Prostate Cancer · research-article; journal article · DOI 10.1155/2012/989214Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.
Tsao CK, Seng S, Oh WK, Galsky MD.
Clin Med Insights Oncol · review-article; journal article · DOI 10.4137/cmo.s6566Contemporary management of metastatic castration-resistant prostate cancer.
Sonpavde G, Sternberg CN.
Curr Opin Urol · research support, non-u.s. gov't; review; journal article · DOI 10.1097/mou.0b013e3283449e19TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S.
Future Oncol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.2217/fon.11.23Current treatment strategies for castration-resistant prostate cancer.
Kim SJ, Kim SI.
Korean J Urol · review-article; journal article · DOI 10.4111/kju.2011.52.3.157Cabazitaxel for the treatment of prostate cancer.
Michielsen DP, Braeckman JG, Denis L.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2011.567268Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ, Antonarakis ES.
Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s13029A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X.
Eur J Cancer · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.ejca.2011.01.001Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N, Sonpavde G, Sartor O.
Future Oncol · journal article · DOI 10.2217/fon.10.168